VDA-1102 Demonstrates Favorable Activity in Mycosis Fungoides
VDA-1102 led to an objective response rate of 56% in patients with mycosis fungoides, according to findings from an interim analysis of a phase 2a study.
Source: onclive.com
Vidac Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Vidac Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Vidac Pharma Today - Breaking & Trending Today
Non-melanoma Skin Cancer Market size to grow at a CAGR of 5.76% from 2021 to 2026, Driven by the NMSC coverage and support
/PRNewswire/ -- The non-melanoma skin cancer market size is forecasted to increase by USD 180.97 million from 2021 to 2026, at a CAGR of 5.76%, according to...
Source: prnewswire.com
Theradiag: Change of Governance
Christian Policard is appointed Chairman of THERADIAG Simon Davière becomes Chief Executive Officer of THERADIAG Regulatory News: The Board of Directors of THERADIAG (ISIN: FR0004197747
Source: finanznachrichten.de
Theradiag: Change of Governance
Christian Policard is appointed Chairman of THERADIAGSimon Davière becomes Chief Executive Officer of THERADIAGCROISSY-BEAUBOURG, France--(BUSINESS WIRE)--Regulatory News:The Board of Directors of THERADIAG (ISIN: FR0004197747, Ticker: ALTER), held on March 1st, 2023, has decided to appoint Mr Christian Policard as...
Source: pharmiweb.com
Non-melanoma Skin Cancer Market size to grow by USD 180.97 Mn with 36% of the growth to originate from North America
/PRNewswire/ -- According to the research report, the Non-melanoma Skin Cancer Market will witness a YOY growth of 5.41 % in 2022 at a CAGR of 5.76% during the...
Source: prnewswire.com